TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06788301

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inferior Alveolar Nerve Block
Description: local anesthesia administration (inferior alveolar nerve block)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR eyeglasses
Description: VR eyeglasses was used to distarct patients from dental environment during inferior alveolar nerve block.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy device
Description: Buzzy device was used to distarct patients from dental environment during inferior alveolar nerve block.
Study: NCT04171817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs
Study: NCT06789016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9%NaCl
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
Study: NCT06789172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN4395
Description: OKN4395 oral dosing twice per day

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks
Study: NCT06448104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling and immersive virtual reality
Description: The study consists of two sessions, separated by a period of two weeks. In the first session, a dry needling procedure based on the Hong technique is performed on the main latent myofascial trigger point of the medial gastrocnemius, vastus medialis quadriceps or biceps femoris muscles.~The procedure will be carried out simultaneously with the use of immersive virtual reality distraction software, applied through MetaQuest 2 virtual reality glasses. This procedure consists of immersive visualization (video and sound images that represent scenes related to relaxation).~In the second session, the same procedure will be repeated, with the addition that the participants will perform 3 sets of 10 repetitions (12RM intensity) of the plantar flexion exercises prior to performing the dry needling technique. of ankle, knee extension or knee flexion (depending on the muscle evaluated) with the aim of stimulating the area to be evaluated, simulating post-exercise fatigue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: The study consists of two sessions, separated by a period of two weeks. In the first session, a dry needling procedure based on the Hong technique is performed on the main latent myofascial trigger point of the medial gastrocnemius, vastus medialis quadriceps or biceps femoris muscles.~In the second session, the same procedure will be repeated, with the addition that the participants will perform 3 sets of 10 repetitions (12RM intensity) of the plantar flexion exercises prior to performing the dry needling technique. of ankle, knee extension or knee flexion (depending on the muscle evaluated) with the aim of stimulating the area to be evaluated, simulating post-exercise fatigue.
Study: NCT05660798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: heated tobacco - lifestyle intervention
Description: Patients unable (unwilling) to stop smoking will be randomized to either combustion (C) or heated (H) tobacco groups.
Study: NCT03883893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous acetaminophen
Description: Intravenous acetaminophen will be given in the OR.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will given if randomized to this group.
Study: NCT03643887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT Capsule DE
Description: 30 capsule one-time oral dose
Study: NCT06701617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: restorative visual rehabitation
Description: black-and-white checkerboard patterns, visual stimulation program, restorative visual rehabitation
Study: NCT06713304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A community-based Protective Behavioral Strategies program
Description: A 5-week group program delivered in a healthcare setting to teach and practice protective behavioral strategies. The objectives of each session are:~Session 1: Setting Safe Drinking Limit: The participants can identify the risk related to their drinking behavior, calculate a standard drink, and set a safe drinking limit.~Session 2: Choosing Nonalcoholic Drinks: The participants can understand the benefits of using nonalcoholic beverages and identify and select nonalcoholic beverages.~Session 3: Planning Ahead: The participants can make a plan to stop using during drinking events and know how to say no to alcohol use.~Session 4: Slowing down drinking: The participants can understand the benefits of slowing down drinking and know how to slow down their drinks.~Session 5: Avoid Risky Drinking Situations: The participants can understand the negative effects of excessive drinking and know how to avoid excessive drinking.
Study: NCT05482516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF.
Study: NCT06730074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using a gamified rehabilitation system in a sitting position involving robots and music for the benefit of individuals with Parkinson's disease (PD)
Description: This is the first socially assistive robotic platform developed specifically for people with PD. If successful, this platform could be incorporated into the clinical toolbox at Adi Negev and other centres.
Study: NCT03643887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 30 capsule one-time oral dose
Study: NCT06729775

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data report back preference by life span
Description: Data report back preference by life span.
Study: NCT05363917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrunix with MTX placebo (+folate)
Description: True Human IgG4 monoclonal antibody that neutralizes Interleukin-1α

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrunix placebo with MTX (+folate)
Description: Natrunix placebo with MTX (+folate)
Study: NCT06789172

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks
Study: NCT05029622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Pamoate
Description: Triptorelin 6-month formulation for IM on day 1 and Month 6.
Study: NCT05465135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin
Description: Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
Study: NCT05690321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opium tincture
Description: Self-administration of opium tincture (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
Study: NCT06789172

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting before first dose of OKN4395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting before first dose of OKN4395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed
Description: Food provided to patient before first OKN4395 dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed
Description: Food provided to patient before first OKN4395 dose
Study: NCT06203340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilizasyon and lumbal back school
Description: Lumbal back schooL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilizasyon and lumbal back school
Description: Lumbal back schooL
Study: NCT06789406

Intervention type: DEVICE
Group type: OTHER
Intervention: Axonics SNM System INS Model 5101 (R20)
Description: Participants treated with the rechargeable Axonics SNM System Model 5101 also referred to as R20. Commercial devices used in this study are within their intended use as described in each geography's approved instructions for use.
Study: NCT06789549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine nasal drops
Description: Patients in experimental arms received 1 mL of 0.1% epinephrine nasal drops before nasotracheal intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxymetazoline nasal drops
Description: Patients in experimental arms received 1 mL of 0.1% oxymetazoline nasal drops before nasotracheal intubation
Study: NCT06780332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDD to Palynziq
Description: Delivery of gradually increasing doses of Palynziq at fixed time intervals over the course of several hours to a cumulative dose equal to the reactive dose. Reactive dose is defined as the dose at which the reactive HSR occurred which led to treatment interruption or reduction of dose or dose frequency.
Study: NCT04663997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: IA of 7.4GBq (± 10%) IV every 6 weeks; maximum 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m2 IV every 3 weeks maximum 12 cycles
Study: NCT06789913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-2608
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RLY-2608 matched-placebo
Study: NCT06789952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: MBSR is a psychological therapeutic intervention that emphasizes the focused, non-judgmental awareness of present-moment experiences without efforts being made to alter or avoid them. It is a practice that is embedded in mind/body and integrative medicine, it combines formal and informal practices of mindfulness.~The formal practices include body scanning, gentle hatha yoga - movements, sitting meditation and walking, meditation. Informal practices include mindfulness of daily activities, such as eating, driving, washing dishes, showering, etc. A variety of other exercises will be used as a support for developing proficiency in the practice of mindfulness. This class places strong emphasis on experiential learning. Each session will include:~* guided instruction while engaging in practices of mindfulness~* opportunity to reflect on experiences and ask questions~* discussion of topics related to the practice of mindfulness as a strategy for reducing stress

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: The lifestyle sessions will include the following topics:~Movement -passive stretches and dynamic stretches, cardio HIIT exercise, flexibility and strength, and core and balance.~Nutrition Body - Include healthy eating with whole, clean, and nutritionally balanced meals; menu planning/prepping, snacking and noticing cravings and feelings of fullness or satiety.~Sleep - Include routine for evening, and morning for optimal sleep, logging routines and quality of sleep, tools to aid in falling asleep, and returning to sleep during the night, eating and sleep patterns Nature/Culture/Arts (with Kemper Museum of Contemporary Art - which will also take place during ½ day retreat) includes spending time in nature and journal experiences, reconnecting with the sun, and surround self with nature.~Financial - Focus on financial wellbeing, budgets/adjustments to budgets, and buying/spending patterns.~Cooking - Include healthy foods, smoothies, juices, kitchen appliances.
Study: NCT06631937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Milk Oligosaccharides
Description: Human Milk Oligosaccharides provided in a commercially available infant formula powder, fed daily ad libitum from enrollement to 6 months of age
Study: NCT05690321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
Study: NCT06631937

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical commercially available infant formula powder without Human Milk Oligosaccharides, fed daily ad libitum from enrollement to 6 months of age
Study: NCT04736173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domvanalimab
Description: Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
Study: NCT05383703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of MNC-168 enteric-coated capsules as a single oral drug
Description: Treatment of live bacterium MNC-168 as a single oral agent as a single oral drug in subjects with advanced malignant solid tumors. First, live fungi can directly or indirectly inhibit tumor growth or induce tumor cell apoptosis through their metabolites or surface proteins, and can also regulate the immune system, especially the tumor microenvironment, to play an antitumor function. Second, tumor immunotherapies exhibit different response levels in different populations, and live bacterial analogs derived from gut microbes may enhance the response to immunotherapy in weakly responding patients.
Study: NCT05399355

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Pulsed Shortwave Treatment with BioElectronics Model 088
Description: Application of 7-30 days of nonthermal, pulsed shortwave (radiofrequency) therapy with BioElectronics Model 088

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Application of 7-30 days of a nonfunctional sham device(s)
Study: NCT05954689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Femoral artery block
Description: Injection on the antero-medial side of the femoral artery of 10mL 0.5% ropivacaine with ultrasound guidance.
Study: NCT04736173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab is a humanized monoclonal antibody targeting human TIGIT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor
Study: NCT05051644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steps 2 Change (S2C)
Description: Participants assigned to S2C and health education control will be scheduled for 60-minute weekly group sessions held over four consecutive weeks in the outpatient OAT clinic. Session 1 will provide pain education including a discussion the biopsychosocial treatment model for chronic pain. Session 2 and 3 will introduce a progressive walking program with individual goals and weekly step count benchmarks and introduce activity pacing to address pain flare ups caused by cycles of over activity and subsequent sedentary behavior.. Veterans will be expected to increase their average step counts by 10% over their prior week's average starting in Session 2. Session 4 will help develop a treatment plan to continue walking and identify possible barriers to meeting goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control will be matched for treatment exposure and individual attention. Treatment discussion will explicitly avoid problems associated with MOUD, substance use, and general self-management strategies. Importantly, group will explicitly avoid talking about pain coping skills and setting goals for daily step targets.
Study: NCT05416515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: 100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days
Study: NCT06392997

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: Saliva sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: Saliva sample
Study: NCT06130436

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Remote Ischemic Conditioning
Description: Sham-Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, 30 min after surgery, the morning of the postoperative day 1, the afternoon of the postoperative day 1, the morning of the postoperative day 2, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning Once Daily
Description: Remote Ischemic Conditioning (at the time points of 30 min before anesthesia, the morning of the postoperative day 1, the morning of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg.~Sham-Remote Ischemic Conditioning (at the time points of 30 min after surgery, the afternoon of the postoperative day 1, the afternoon of the postoperative day 2): Three cycles (30 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff, but the cuff pressure will be 0 mmHg.